A partir de cette page vous pouvez :
Retourner au premier écran avec les dernières notices... |
Descripteurs (mots clés)
Thésaurus Mesh
> A > Acuité visuelle > Acuité visuelle / effets des médicaments et des substances chimiques
Acuité visuelle / effets des médicaments et des substances chimiques
Ajouter le résultat dans votre panier Affiner la recherche
Etendre la recherche sur niveau(x) vers le bas
Randomized Controlled Trial of a Spectacle Lens for Macular Degeneration / Martijn S. Visser in OVS : Optometry & Vision Science, vol. 97, 10 (Octobre 2020)
[article]
in OVS : Optometry & Vision Science > vol. 97, 10 (Octobre 2020)
Titre : Randomized Controlled Trial of a Spectacle Lens for Macular Degeneration Type de document : article de périodique Auteurs : Martijn S. Visser ; Reinier Timman ; Joanneke Kampen-Smalbrugge ; Jan Roelof Polling Année de publication : 2020 Langues : Français (fre) Descripteurs (mots clés) : [Thésaurus Mesh]:A:Acuité visuelle:Acuité visuelle / effets des médicaments et des substances chimiques
[Thésaurus Mesh]Dégénérescence maculaire
[Thésaurus Mesh]Lentilles optiques
[Thésaurus Mesh]Lunettes correctrices
[Thésaurus Mesh]Qualité de vie
[Thésaurus Mesh]Troubles de la vision
[Thésaurus Mesh]Vision oculaireRésumé : SIGNIFICANCE: E-Scoop, a spectacle lens, provides no clinically relevant improvements on quality of life, visual acuity, and contrast sensitivity for patients with AMD. Because patients' burden is high and therapeutic options are scarce, the incentive to develop effective vision rehabilitation interventions remains. PURPOSE: Patients with AMD experience low quality of life due to vision loss, despite angiogenesis inhibitor interventions that slow down progression for some patients. E-Scoop, which includes low-power prisms, 6% magnification, yellow tint, and antireflection coating, might aid in daily activities by improving distance viewing. Separately, these features have little proven effectiveness. E-Scoop has not been formally tested. This study aimed to determine the impact of E-Scoop on quality of life and the effect on visual acuity and contrast sensitivity. METHODS: In this randomized controlled, open-label trial, 190 of 226 eligible patients were included. The primary outcome was quality of life measured with the 25-item National Eye Institute Visual Function Questionnaire. Secondary outcomes were visual acuity and contrast sensitivity. The follow-up for quality of life was after 6 weeks for controls and after 3 weeks of use for E-Scoop wearers. The visual measures were repeated after 6 weeks, with optimal refractive correction, with and without E-Scoop. RESULTS: Randomization resulted in 99 E-Scoop and 86 control group patients for intention-to-treat analysis. No differential change was found between the E-Scoop and control groups on the 25-item National Eye Institute Visual Function Questionnaire using Rasch analysis (Cohen d = −0.07, P = .53). Statistically significant but small effects were found in favor of E-Scoop on binocular visual acuity (mean difference, 0.05 logMAR [2.5 letters, P < .001]) and contrast sensitivity (mean difference, 0.10 logCS [2 letters, P < .001]). CONCLUSIONS: No effect of E-Scoop on quality of life was found. E-Scoop showed effects that were statistically significant, although not clinically meaningful and within typical variability, on visual measures. Permalink : https://bibliotheque.helb-prigogine.be/opac_css/index.php?lvl=notice_display&id= [article]Exemplaires
Cote Support Localisation Section Disponibilité aucun exemplaire Topical Review: Pilocarpine-induced Miosis as Help for Early Presbyopes? / Gerald Westheimer in OVS : Optometry & Vision Science, vol. 99, 08 (Aout 2022)
[article]
in OVS : Optometry & Vision Science > vol. 99, 08 (Aout 2022)
Titre : Topical Review: Pilocarpine-induced Miosis as Help for Early Presbyopes? Type de document : article de périodique Auteurs : Gerald Westheimer Année de publication : 2022 Langues : Français (fre) Descripteurs (mots clés) : [Thésaurus Mesh]:A:Acuité visuelle:Acuité visuelle / effets des médicaments et des substances chimiques
[Thésaurus Mesh]:P:Presbytie:Presbytie / thérapie
[Thésaurus Mesh]Pilocarpine
[Thésaurus Mesh]Presbytie
[Thésaurus HELB]:Optique:solution ophtalmiqueRésumé : SIGNIFICANCE: The clinical utility of ophthalmic pilocarpine-induced pupil constriction to help overcome image blur of close-up targets in patients with failing accommodation is examined. Pilocarpine in low-concentration ophthalmic solution eye drops constricts the pupil to approximately 2 mm and thus reduces defocus blur. To gain regulatory approval of this drug for the treatment of presbyopia, clinical trials were conducted with 1.25% pilocarpine. Near vision was improved in a modest proportion of early presbyopes: between 12 and 22% more patients reached criterion near visual acuity than with a placebo, depending on conditions. The drug is well tolerated, and its effect has onset of only minutes and lasts several hours. Small pupils will cause diminished night vision and may have an impact on distance acuity to which possible minor drug-induced accommodative spasms could contribute. The therapy has a role for patients who want to postpone or briefly pause dioptric supplementation of their failing accommodation. No convincing case has been made for one version of ophthalmic pilocarpine over another. Permalink : https://bibliotheque.helb-prigogine.be/opac_css/index.php?lvl=notice_display&id= [article]Exemplaires
Cote Support Localisation Section Disponibilité aucun exemplaire